Core Viewpoint - Jincheng Pharmaceutical announced the transfer of production technology and licensing rights for "Progesterone Vaginal Soft Capsules" to Haimeini (Shanghai) Pharmaceutical Technology Co., Ltd. for a total fee of 50 million RMB [2] Group 1 - Jincheng Pharmaceutical's wholly-owned subsidiary, Beijing Jincheng Taier Pharmaceutical Co., Ltd., is involved in the transaction [2] - The product being transferred is "Progesterone Vaginal Soft Capsules" (brand name: Langyigeng Baifen®), for which Jincheng Taier holds the drug approval number [2] - The total transaction fee, including tax, is set at 50 million RMB [2]

Core Viewpoint - Jincheng Pharmaceutical (300233.SZ) announced the transfer of production technology and marketing rights for "Progesterone Vaginal Soft Capsules" to Haimerni (Shanghai) Pharmaceutical Technology Co., Ltd. for a total fee of 50 million yuan, which aligns with Jincheng Tail's product development strategy and aims to optimize its product structure and asset efficiency [1][1][1] Group 1 - Jincheng Tail, a wholly-owned subsidiary of Jincheng Pharmaceutical, holds the drug approval number for "Progesterone Vaginal Soft Capsules" (brand name: Langyigengbaifen®) [1] - The total transaction fee for the transfer of rights is 50 million yuan, including tax [1] - The transfer is expected to enhance Jincheng Tail's asset operation efficiency and further optimize its asset structure [1]

Core Viewpoint - Jincheng Pharmaceutical (300233.SZ) announced the transfer of production technology and marketing rights for "Progesterone Vaginal Soft Capsules" to Haimerni (Shanghai) Pharmaceutical Technology Co., Ltd for a total fee of 50 million yuan, which aligns with Jincheng Tail's product development strategy and aims to optimize its product structure and asset efficiency [1] Group 1 - Jincheng Tail, a wholly-owned subsidiary of Jincheng Pharmaceutical, holds the drug approval number for "Progesterone Vaginal Soft Capsules" (brand name: Langyigengbaifen®) [1] - The total transaction fee for the transfer of rights is 50 million yuan, including tax [1] - The transfer is expected to enhance Jincheng Tail's asset operation efficiency and further optimize its asset structure [1]

Core Viewpoint - Jincheng Pharmaceutical's subsidiary, Beijing Jincheng Tail Pharmaceutical Co., Ltd., plans to transfer its rights to the production technology and marketing authorization of "Progesterone Vaginal Soft Capsules" to Haimerni (Shanghai) Pharmaceutical Technology Co., Ltd. for a total fee of RMB 50 million [1] Group 1 - The transfer involves the production technology and marketing rights of "Progesterone Vaginal Soft Capsules" (brand name: Langyigeng Baofen) [1] - The total transaction fee is RMB 50 million, which has been agreed upon by both parties after considering the actual value of the product rights and market conditions [1]

Core Viewpoint - Jincheng Pharmaceutical (300233.SZ) announced the transfer of production technology and market authorization rights for "Progesterone Vaginal Soft Capsules" to Haimerni (Shanghai) Pharmaceutical Technology Co., Ltd for a total fee of RMB 50 million [1] Group 1 - Jincheng Pharmaceutical's wholly-owned subsidiary, Beijing Jincheng Tail Pharmaceutical Co., Ltd, is involved in the transaction [1] - The product being transferred is "Progesterone Vaginal Soft Capsules," marketed under the name "Langyigeng Baofen" [1] - The agreed transfer fee of RMB 50 million has been determined based on the actual value of the product rights and market conditions [1]